U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07685548) titled 'AI-Driven Tumor Response Evaluation for Solid Tumors' on June 28.
Brief Summary: Purpose: This study is developing and validating an artificial intelligence (AI)-driven system to evaluate tumor response using changes in total tumor volume. The goal is to determine whether this AI-based approach can better predict patient survival compared with the current standard method (RECIST), which relies on linear measurements of a few selected tumors.
Participants: The study includes both retrospective and prospective cohorts. The retrospective cohort includes approximately 6,000 patients with solid tumors who received non-surgical treatment ...